USA - NASDAQ:ILMN - US4523271090 - Common Stock
The current stock price of ILMN is 121.98 USD. In the past month the price increased by 34.73%. In the past year, price decreased by -9.22%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 26.25 | 222.04B | ||
| DHR | DANAHER CORP | 28.46 | 157.10B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 167.64 | 50.87B | ||
| A | AGILENT TECHNOLOGIES INC | 27.8 | 42.96B | ||
| IQV | IQVIA HOLDINGS INC | 18.99 | 37.55B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 34.6 | 29.82B | ||
| WAT | WATERS CORP | 30.5 | 23.06B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 38.73 | 19.69B | ||
| MEDP | MEDPACE HOLDINGS INC | 41.79 | 16.79B | ||
| TEM | TEMPUS AI INC | N/A | 12.35B | ||
| RVTY | REVVITY INC | 19.65 | 10.93B | ||
| TECH | BIO-TECHNE CORP | 31.81 | 9.56B |
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company is headquartered in San Diego, California and currently employs 8,970 full-time employees. The company went IPO on 2000-06-28. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
ILLUMINA INC
5200 Illumina Way
San Diego CALIFORNIA 92122 US
CEO: Francis A. deSouza
Employees: 9000
Phone: 18582024500
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company is headquartered in San Diego, California and currently employs 8,970 full-time employees. The company went IPO on 2000-06-28. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
The current stock price of ILMN is 121.98 USD. The price decreased by -0.51% in the last trading session.
ILMN does not pay a dividend.
ILMN has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
ILMN stock is listed on the Nasdaq exchange.
You can find the ownership structure of ILLUMINA INC (ILMN) on the Ownership tab.
ChartMill assigns a technical rating of 8 / 10 to ILMN. When comparing the yearly performance of all stocks, ILMN turns out to be only a medium performer in the overall market: it outperformed 61.3% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to ILMN. While ILMN belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
Over the last trailing twelve months ILMN reported a non-GAAP Earnings per Share(EPS) of 4.36. The EPS increased by 152.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 29.37% | ||
| ROA | 20.67% | ||
| ROE | 55.71% | ||
| Debt/Equity | 0.66 |
28 analysts have analysed ILMN and the average price target is 114.15 USD. This implies a price decrease of -6.42% is expected in the next year compared to the current price of 121.98.
For the next year, analysts expect an EPS growth of 93.48% and a revenue growth -1.07% for ILMN